GS-3242 + Lenacapavir for HIV

This trial tests new treatments, GS-3242 and Lenacapavir, to determine if they outperform the current treatment, Biktarvy, for individuals with controlled HIV. Researchers aim to assess whether switching medications can maintain effective virus suppression. Participants will either continue with Biktarvy or switch to the new treatments, and the study will compare the outcomes. Ideal candidates for this trial are those with HIV-1 who have maintained control with Biktarvy for at least six months, without any history of certain drug resistances. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in HIV treatment.

The trial involves switching from your current medication, Biktarvy, to the study drugs GS-3242 and Lenacapavir. You will need to stop taking Biktarvy if you participate in the trial.

Research has shown that GS-3242 and Lenacapavir (LEN) are generally well-tolerated. Previous studies found no major safety concerns with GS-3242. It effectively reduced HIV levels and remained in the body for an extended period. Importantly, no serious side effects led to discontinuation of the treatment. Similarly, Lenacapavir has shown good tolerance in other studies, demonstrating effective virus control. Although these treatments are still under investigation and not yet approved, early findings suggest they are safe for further research.¹²³⁴⁵

Researchers are excited about GS-3242 in combination with Lenacapavir (LEN) for treating HIV because it introduces a novel approach with potentially longer-lasting effects. Unlike current treatments, which often require daily oral medication, this combination involves initial oral doses followed by intramuscular injections, allowing for less frequent dosing. Additionally, Lenacapavir is a capsid inhibitor, which targets a different part of the HIV lifecycle compared to most standard treatments, potentially offering a new way to control the virus. This could lead to greater convenience and adherence for patients, reducing the burden of daily medication.

This trial will examine the combination of GS-3242 and Lenacapavir in different groups. Studies have shown that GS-3242, when combined with Lenacapavir, reduces the amount of HIV in the blood. This combination aims to maintain low virus levels, known as viral suppression. Research indicates that GS-3242 is highly effective against the virus and remains in the body for an extended period, potentially allowing for less frequent dosing. Initial findings suggest that Lenacapavir lowers the risk of spreading HIV. Together, these drugs are being studied for their ability to control HIV in individuals who already have low virus levels.¹²³⁴⁵